At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
Alirocumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of REGN727 in Patients With Heterozygous Familial Hypercholesterolemia
In Brief
A Phase 2 clinical trial evaluating Alirocumab and Placebo for Hypercholesterolemia. Completed, enrolled 77 participants across 22 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesCanada, United States
CollaboratorsSanofi
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartJan 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedDec 24, 2010
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.5 years ago
Interventions
Alirocumabdrug
Alirocumab two SC injections in the abdomen only.
Placebodrug
Placebo two SC injections in the abdomen only.